Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMKNCVM)

Drug Name
Dalcetrapib Drug Info
Synonyms JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate
Cross-matching ID
PubChem CID
6918540
ChEBI ID
CHEMBL95001
CAS Number
CAS 211513-37-0
TTD Drug ID
D05SSC
INTEDE Drug ID
DR1890

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.37 0.00e+0 44/46 (95.65%) PSMD11;PSMC3;PSMB3;...
Spliceosome 2.29 0.00e+0 101/150 (67.33%) LSM6;LSM5;SRSF7;...
Ribosome biogenesis in eukaryotes 2.17 0.00e+0 52/108 (48.15%) NXT1;EIF6;RPP40;...
Base excision repair 1.85 1.05e-2 29/33 (87.88%) PARP2;POLE2;APEX1;...
Nucleotide excision repair 1.81 1.35e-2 40/47 (85.11%) RPA3;RFC3;XPA;...
DNA replication 1.73 3.79e-2 34/36 (94.44%) RPA3;RFC3;POLE2;...
Systemic lupus erythematosus -1.62 4.46e-2 45/135 (33.33%) HLA-DPB1;C7;CTSG;...
Cysteine and methionine metabolism -1.63 4.29e-2 43/50 (86%) CBS;ADI1;AHCYL2;...
mTOR signaling pathway -1.64 4.10e-2 114/154 (74.03%) PIK3CB;FLCN;FZD3;...
Other glycan degradation -1.64 4.23e-2 13/18 (72.22%) AGA;HEXB;FUCA1;...
Glycine, serine and threonine metabolism -1.64 4.37e-2 31/40 (77.5%) CBS;DLD;SHMT2;...
Amoebiasis -1.65 4.16e-2 99/102 (97.06%) CASP3;COL4A5;SERPINB10;...
Ether lipid metabolism -1.65 4.20e-2 32/49 (65.31%) PLA2G2A;AGPS;GDPD3;...
Aldosterone-regulated sodium reabsorption -1.67 3.90e-2 34/37 (91.89%) ATP1B2;NR3C2;PIK3CB;...
Cardiac muscle contraction -1.67 3.68e-2 64/87 (73.56%) HRC;ATP1B1;COX5A;...
Sphingolipid metabolism -1.68 3.84e-2 32/49 (65.31%) ARSA;SGMS1;GLA;...
Folate biosynthesis -1.68 3.94e-2 23/26 (88.46%) AKR1C3;SPR;AKR1B10;...
Fatty acid elongation -1.68 4.05e-2 19/27 (70.37%) TECR;ELOVL4;ACOT7;...
beta-Alanine metabolism -1.70 3.79e-2 25/30 (83.33%) ACOX1;DPYD;ABAT;...
Rheumatoid arthritis -1.72 3.32e-2 78/93 (83.87%) ATP6V1H;IL17A;ITGB2;...
Histidine metabolism -1.72 3.22e-2 16/22 (72.73%) ALDH2;AOC1;HNMT;...
Autophagy -1.74 3.01e-2 113/169 (66.86%) PIK3CB;MAP2K1;NRBF2;...
Viral protein interaction with cytokine and cytokine re... -1.74 3.21e-2 84/100 (84%) CCL11;CCL23;CXCL12;...
Biosynthesis of unsaturated fatty acids -1.78 1.84e-2 21/27 (77.78%) TECR;ELOVL4;ACOT7;...
Arginine and proline metabolism -1.78 2.07e-2 39/50 (78%) SAT1;OAT;ALDH2;...
Collecting duct acid secretion -1.79 1.89e-2 22/27 (81.48%) ATP6V0A1;ATP6V0A4;ATP6V1E1;...
Staphylococcus aureus infection -1.85 1.29e-2 72/95 (75.79%) DEFA6;KRT17;HLA-DPB1;...
Tryptophan metabolism -1.86 1.55e-2 35/42 (83.33%) DLD;IDO1;ALDH2;...
Intestinal immune network for IgA production -1.88 1.38e-2 38/48 (79.17%) IL15RA;IL10;IL2;...
Steroid biosynthesis -1.89 1.47e-2 19/20 (95%) CYP24A1;TM7SF2;SC5D;...
Lysosome -2.12 0.00e+0 115/128 (89.84%) PPT1;MCOLN1;HEXB;...
Ferroptosis -2.25 0.00e+0 36/41 (87.8%) TFRC;CYBB;FTH1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 80uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 80uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 80uM 6H
HT-29 CVCL_0320 Homo sapiens 80uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 80uM 6H
MDST8 CVCL_1400 Homo sapiens 80uM 6H
NCI-H508 CVCL_1561 Homo sapiens 80uM 6H
SNU-1040 CVCL_5001 Homo sapiens 80uM 6H
SNU-C4 CVCL_5008 Homo sapiens 80uM 6H
SNU-C5 CVCL_5009 Homo sapiens 80uM 6H
SW480 CVCL_0546 Homo sapiens 80uM 6H
SW620 CVCL_0547 Homo sapiens 80uM 6H
SW948 CVCL_0550 Homo sapiens 80uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 80uM 6H
RKO CVCL_0504 Homo sapiens 80uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 80uM 6H
SNG-M CVCL_1707 Homo sapiens 80uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 80uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 80uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 80uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 80uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 80uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 80uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 80uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 80uM 6H
T3M-10 CVCL_1729 Homo sapiens 80uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 80uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 80uM 6H
HCC515 CVCL_5134 Homo sapiens 80uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 80uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 80uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 80uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 80uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 80uM 6H
OV7 CVCL_1623 Homo sapiens 80uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 80uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 80uM 6H
RMUG-S CVCL_1666 Homo sapiens 80uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 80uM 6H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 80uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 80uM 6H
PL-21 CVCL_2161 Homo sapiens 80uM 6H
SKM-1 CVCL_0010 Homo sapiens 80uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 80uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 80uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 80uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 80uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 80uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 80uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 80uM 6H